CNX Therapeutics acquires Tacrolimus infusion from Pharmanovia, strengthening Critical Care portfolio

London, England – Thursday 2 April: CNX Therapeutics Limited ("CNX Therapeutics"), a specialty pharmaceutical company focused on improving patient access to essential medicines, today announced it has acquired the rights to Tacrolimus 5 mg/ml concentrate for solution for infusion from Pharmanovia. The transaction was signed on 1 April 2026.

Tacrolimus infusion is used in hospital settings to prevent organ rejection in liver, kidney and heart transplant patients. It will be the first generic version of the originator Prograf® (Astellas Pharma), a clinically established product with a long track record in critical care.

“We are pleased to add Tacrolimus infusion to our growing Critical Care portfolio,” said Guy Clark, Chief Executive Officer of CNX Therapeutics. “It is a clinically important product for some of the most vulnerable patients in hospital settings, and we are committed to ensuring it reaches the patients that need it.”

The acquisition supports CNX Therapeutics’ strategy to build a leading European specialty pharmaceutical platform, with a focus on Critical Care and CNS. Commercial launch is planned across Germany, France and Spain, with the UK to follow.

"Tacrolimus infusion has historically been served only by the originator product”, said Ben Moore, Vice President of Corporate Development at CNX Therapeutics. “Securing the first generic version for European markets represents a strong commercial opportunity, and one that we believe will meaningfully improve patient access to an established treatment.”

CNX Therapeutics was acquired by Inflexion Private Equity, a leading mid-market private equity firm, in 2021, and was selected as one of four high-performing portfolio companies for Inflexion's £2.3bn continuation fund in 2025.